Nicole Boyle
Psychiatric/Mental Health · Ammon, IDNPI 1275266991
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $846, 8.9 times the $95 reported in 2022.
Across 108 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$462
- Otsuka America Pharmaceutical, Inc.$354
- Teva Pharmaceuticals USA, Inc.$236
- AbbVie$203
- Neurocrine Biosciences, Inc.$139
- Axsome Therapeutics, Inc.$115
- plus $520 from 12 others
What the payments were for
- Food & beverage$2,029100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$125
How this compares
$2,029 in reported general payments places this provider in the 75th percentile of 221 psychiatric/mental health providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 36 | $50,056 |
| CaplytaLumateperone Tosylate | 24 | $36,454 |
| RexultiBrexpiprazole | 22 | $35,575 |
| TrintellixVortioxetine Hydrobromide | 16 | $10,750 |
| DayvigoLemborexant | 14 | $3,721 |
| Lisdexamfetamine Dimesylate | 16 | $3,720 |
| Atomoxetine Hcl | 13 | $2,422 |
| Vilazodone Hcl | 19 | $2,162 |
| Bupropion XlBupropion Hcl | 21 | $1,388 |
| Trazodone Hcl | 59 | $802 |
| Propranolol Hcl | 24 | $443 |
| Hydroxyzine Hcl | 20 | $411 |
| Quetiapine Fumarate | 32 | $409 |
| Prazosin Hcl | 12 | $275 |
| Methylphenidate Hcl | 17 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $203 | $50,05636 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $462 | $36,45424 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $354 | $35,57522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Ammon
- Benjamin PixtonAmmon$3K
- Jayde BarnesAmmon$3K
- Sara LarsenAmmon$2K
- Christopher JankowskiAmmon$2K
- Jason MartinIdaho Falls$78K
- Misti NewsonBoise$56K
- Jared PetrickCoeur D Alene$32K
- Carey CrillBoise$19K
- Deborah RushMeridian$13K
- Ashley CroftCaldwell$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.